According to the analysis, a higher expression of FGFR3 was recorded in the lung, breast, and liver cancers, whereas its expression was significantly decreased in prostate and pancreas cancerous states compared with the respective normal tissues (Fig 4). This evidence concerns the gene FGFR3 and liver cancer.